Jianpeng Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianpeng Yu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chen Jin
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Cheng Su
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Christopher J. Pirozzi
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
13 shared publications - Daniel J. George
Duke Cancer Institute Durham North Carolina USA
13 shared publications - David M. Ashley
Duke University
13 shared publications - David Moon
The University of Newcastle upon Tyne
13 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-11
PCAT1 Supports Partial AR-V7 Function and Promotes Enzalutamide Resistance in Prostate Cancer
Background: Enzalutamide resistance (Enz-R) remains a major clinical challenge in advanced prostate cancer (PCa). Here, we identified resistance-associated long non-coding RNA (lncRNA) PCAT1 and investigated its functional relevance in Enz-R PCa. Methods: Public transcriptomic datasets, bioinformatic analyses, RNA immunoprecipitation (RIP), ChIP-qPCR, and in vitro and in vivo functional assays were used to evaluate the expression, function, and potential mechanism of PCAT1 in Enz-R PCa models. Results: PCAT1 was upregulated in Enz-R PCa models and was associated with adverse clinical features. PCAT1 knockdown inhibited the growth of C4-2 Enz-R cells and 22Rv1 cells and suppressed tumor growth in vivo. Mechanistically, PCAT1 was associated with AR/AR-V7 and supported selected AR-V7-associated downstream outputs without markedly altering AR-V7 protein expression. AR-V7 ChIP-qPCR further suggested that PCAT1 knockdown reduced AR-V7 enrichment at selected regulatory regions, including the KLK3 and PMEPA1 enhancers. In addition, high-dose androgen treatment reduced PCAT1 and AR-V7 expression in our experimental model. Conclusion: PCAT1 contributes to Enz-R PCa growth and may support selected AR-V7-associated transcriptional outputs. PCAT1 may represent a potential therapeutic vulnerability, and the relationship between high-dose androgen treatment, PCAT1 suppression, and AR-V7 signaling warrants further investigation.
- 1 July 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-11
Open AccessPCAT1 Supports Partial AR-V7 Function and Promotes Enzalutamide Resistance in Prostate Cancer
Background: Enzalutamide resistance (Enz-R) remains a major clinical challenge in advanced prostate cancer (PCa). Here, we identified resistance-associated long non-coding RNA (lncRNA) PCAT1 and investigated its functional relevance in Enz-R PCa. Methods: Public transcriptomic datasets, bioinformatic analyses, RNA immunoprecipitation (RIP), ChIP-qPCR, and in vitro and in vivo functional assays were used to evaluate the expression, function, and potential mechanism of PCAT1 in Enz-R PCa models. Results: PCAT1 was upregulated in Enz-R PCa models and was associated with adverse clinical features. PCAT1 knockdown inhibited the growth of C4-2 Enz-R cells and 22Rv1 cells and suppressed tumor growth in vivo. Mechanistically, PCAT1 was associated with AR/AR-V7 and supported selected AR-V7-associated downstream outputs without markedly altering AR-V7 protein expression. AR-V7 ChIP-qPCR further suggested that PCAT1 knockdown reduced AR-V7 enrichment at selected regulatory regions, including the KLK3 and PMEPA1 enhancers. In addition, high-dose androgen treatment reduced PCAT1 and AR-V7 expression in our experimental model. Conclusion: PCAT1 contributes to Enz-R PCa growth and may support selected AR-V7-associated transcriptional outputs. PCAT1 may represent a potential therapeutic vulnerability, and the relationship between high-dose androgen treatment, PCAT1 suppression, and AR-V7 signaling warrants further investigation.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
A graphical abstract summarizing tumor cells’ strategies for adapting to and their vulnerabilities under purine shortage stress.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
A graphical abstract summarizing tumor cells’ strategies for adapting to and their vulnerabilities under purine shortage stress.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
The MTAP-dependent purine salvage is a source of purine supply for cancer cells.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
The MTAP-dependent purine salvage is a source of purine supply for cancer cells.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Treating tumor-bearing mice with DRP-104 in combination with MTDIA does not affect animal’s body weight but alters the tumor’s immune microenvironment.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Treating tumor-bearing mice with DRP-104 in combination with MTDIA does not affect animal’s body weight but alters the tumor’s immune microenvironment.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Supplementary Table 1. Metabolite profiling of C4-2 and PC3 cells (LC-MS profiling results normalzied by cell confluency).
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Supplementary Table 1. Metabolite profiling of C4-2 and PC3 cells (LC-MS profiling results normalzied by cell confluency).
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DRP-104 simulates DNA damage and the cGAS-STING pathway.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DRP-104 simulates DNA damage and the cGAS-STING pathway.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DON inhibits FGAMS, a de novo purine biosynthesis enzyme, with the lowest Ki.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DON inhibits FGAMS, a de novo purine biosynthesis enzyme, with the lowest Ki.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Data from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Purpose:Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear.Experimental Design:Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models.Results:We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity.Conclusions:Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
Purpose:Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear.Experimental Design:Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models.Results:We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity.Conclusions:Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DRP-104 affects purine metabolism and purine supply.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
DRP-104 affects purine metabolism and purine supply.